This is unpublished

Sunil R.

he, him, his
Physician & Research Faculty
Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center
Professor, Public Health Sciences Division, Fred Hutch
Raisbeck Endowed Chair for Pancreatic Research, Fred Hutch
Professor, Division of Medical Oncology, University of Washington
Sites of Practice
Seattle Cancer Care Alliance

Photo: Fred Hutch

Education, Training, Board Certifications 

  • M.D., Yale University 
  • Ph.D., Yale University 
  • Residency in Internal Medicine, Brigham and Women's Hospital 
  • Fellowship in Hematology/Oncology, Dana-Farber/Partners Cancer Care Program

Clinical Expertise

  • Pancreatic cancer



Research and/or clinical interests 

Dr. Sunil Hingorani is a gastrointestinal medical oncologist and the founding director of the multi-disciplinary Pancreas Cancer Specialty Clinic at the Seattle Cancer Care Alliance. He additionally serves as the Director of the Center for Accelerated Translation in Pancreas Cancer and Deputy Director of Seattle Translational Tumor Research for the Cancer Center Consortium. The Hingorani laboratory investigates the cellular and molecular mechanisms of pathogenesis of pancreatic ductal adenocarcinoma (PDA) and has undertaken a systematic effort to deconstruct the cell autonomous and non-cell autonomous factors that drive this unusually aggressive and lethal disease. To this end, Dr. Hingorani has helped develop a number of genetically engineered animal models of preinvasive, invasive and metastatic PDA involving the targeted endogenous expression of key mutations implicated in human PDA. These models faithfully recapitulate the clinical syndrome, histopathology and molecular features of the cognate human conditions, including the often unique features of the stromal and immune responses that constitute the complex desmoplasia of this disease. These model systems have enabled numerous seminal studies of pancreas cancer pathogenesis by his and other laboratories around the world. These models also serve as the primary platforms for the Murine Clinical Trials Program at Fred Hutch designed to increase the predictive power of preclinical investigations and accelerate the translation of effective early detection, chemopreventive and treatment strategies for PDA to the clinic. Both Dr. Hingorani’s clinical practice and research endeavors are 100 percent devoted to pancreas cancer.